Meta-Analysis of PDE5 Inhibitors for Cerebral Small Vessel Disease, 236 Patients

A systematic review and meta-analysis of four randomized controlled trials from 1990 to 2025, involving 236 patients, evaluating phosphodiesterase-5 inhibitors for cerebral small vessel disease. The dataset, authored by Lingwan Yan and last updated in April 2026, synthesizes outcomes on cerebral hemodynamics, cognitive function, and adverse events.

Use Cases

• Validate meta-analysis findings on cerebral blood flow changes in white matter hyperintensity regions.
• Assess the safety profile of PDE5 inhibitors based on the reported risk ratio for adverse events.
• Investigate the relationship between diastolic blood pressure reduction and cerebral hemodynamic parameters.
• Benchmark cognitive assessment outcomes against other therapeutic interventions for vascular cognitive decline.

Strengths

• Includes data from four randomized controlled trials with a total of 236 patients.
• Provides specific quantitative results, such as a mean difference of 1.31 mL/100 g/min for cerebral blood flow.
• Clear temporal coverage from January 1990 to October 2025 for the literature search.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 11.0 KB, indicating limited scope.

Provenance

Source

Lingwan Yan

Collection Method

Systematic review and meta-analysis of four major databases.

Time Range

Literature search from January 1990 to October 2025.

Freshness

Last updated 2026-04-13 04:35:28; freshness should be verified.

Geography

null